Drug Patents Expiring in 2034

1. List of Abilify Maintena Kit drug patents

ABILIFY MAINTENA KIT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Mar, 2034

(10 years from now)

Do you want to check out ABILIFY MAINTENA KIT patents from before 2022?

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Maintenance monotherapy treatment of bipolar 1 disorder; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's patent expiration?
More Information on Dosage

ABILIFY MAINTENA KIT family patents

6

United States

2. List of Abraxane drug patents

ABRAXANE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511046 BRISTOL MYERS SQUIBB CO Methods of treating pancreatic cancer
Jan, 2034

(10 years from now)

US9511046

(Pediatric)

BRISTOL MYERS SQUIBB CO Methods of treating pancreatic cancer
Jul, 2034

(11 years from now)

Do you want to check out ABRAXANE patents from before 2022?
Exclusivity Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's patent expiration?
More Information on Dosage

ABRAXANE family patents

6

United States

3

Japan

2

New Zealand

2

China

1

Australia

1

Israel

1

Croatia

1

Korea, Republic of

1

Canada

1

Denmark

1

Spain

1

Portugal

1

Poland

1

Hong Kong

1

Slovenia

1

Mexico

1

RS

1

Brazil

1

South Africa

1

Hungary

1

Lithuania

1

European Union

3. List of Adempas drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10662188 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Feb, 2034

(10 years from now)

US11203593 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
Feb, 2034

(10 years from now)

Do you want to check out ADEMPAS patents from before 2022?

Drugs and Companies using RIOCIGUAT ingredient

Market Authorisation Date: 08 October, 2013

Treatment: Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who f...

Dosage: TABLET;ORAL

How can I launch a generic of ADEMPAS before it's patent expiration?
More Information on Dosage

ADEMPAS family patents

6

United States

3

Canada

3

European Union

1

Australia

EA

1

EA

1

Dominican Republic

1

Korea, Republic of

1

Tunisia

1

Peru

1

Costa Rica

1

Nicaragua

1

Chile

1

Singapore

1

Philippines

1

Japan

1

Morocco

1

Hong Kong

1

Mexico

1

Cuba

1

China

1

Brazil

4. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415008 TEVA PHARM Dry powder inhaler
Oct, 2034

(11 years from now)

US9066957 TEVA PHARM Dry powder inhaler
Oct, 2034

(11 years from now)

Do you want to check out AIRDUO DIGIHALER patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: Treatment of asthma

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

9

United States

3

Australia

3

Hong Kong

EA

2

EA

2

Korea, Republic of

2

Canada

2

Peru

2

Chile

2

Japan

2

Mexico

2

Argentina

2

China

2

Taiwan

2

European Union

1

Colombia

1

Israel

1

New Zealand

1

Denmark

1

Spain

1

Portugal

1

Philippines

1

Poland

1

Morocco

1

Brazil

1

South Africa

1

Hungary

5. List of Alkindi Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649280 ETON Composition comprising hydrocortisone
May, 2034

(10 years from now)

Do you want to check out ALKINDI SPRINKLE patents from before 2022?

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage

ALKINDI SPRINKLE family patents

3

United Kingdom

1

Australia

1

Israel

1

Croatia

1

Korea, Republic of

1

Canada

1

New Zealand

1

Denmark

1

Spain

1

Portugal

1

Russia

1

Poland

1

Japan

1

Hong Kong

1

Slovenia

1

Mexico

1

RS

1

China

1

South Africa

1

Brazil

1

Hungary

1

United States

1

Lithuania

1

European Union

6. List of Alunbrig drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(10 years from now)

Do you want to check out ALUNBRIG patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage

7. List of Arikayce Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566234 INSMED INC Systems for treating pulmonary infections
Jan, 2034

(10 years from now)

Do you want to check out ARIKAYCE KIT patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

10

United States

5

Japan

4

Australia

2

Korea, Republic of

2

New Zealand

2

China

2

European Union

1

Colombia

1

Israel

1

Croatia

1

Canada

1

Denmark

1

Spain

1

Portugal

1

Russia

1

Poland

1

Hong Kong

1

Slovenia

1

Mexico

1

Brazil

1

Lithuania

8. List of Aubagio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Feb, 2034

(10 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Aug, 2034

(11 years from now)

Do you want to check out AUBAGIO patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or adm...

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

AUBAGIO family patents

4

United States

1

European Union

9. List of Austedo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(10 years from now)

US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(10 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(10 years from now)

US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(10 years from now)

Do you want to check out AUSTEDO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
M (M) Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's patent expiration?
More Information on Dosage

10. List of Auvelity drug patents

AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517542 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10933034 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10251879 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10092561 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US10894046 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11191739 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10874664 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10080727 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11197839 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11147808 AXSOME Method of decreasing the fluctuation index of dextromethorphan
Nov, 2034

(11 years from now)

US11207281 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11141416 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11141388 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11213521 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11129826 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11123343 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10966974 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10512643 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10105361 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10105327 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10092560 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9968568 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11510918 AXSOME NA
Nov, 2034

(11 years from now)

US11478468 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11497721 AXSOME NA
Nov, 2034

(11 years from now)

US11524008 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11524007 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11517543 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10463634 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11541048 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11541021 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11534414 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11617747 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11617728 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11596627 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11382874 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11364233 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9457025 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US10058518 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9278095 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9867819 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9168234 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9861595 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9700553 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11357744 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11344544 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9486450 AXSOME Hydroxybupropion and related compounds as modulators of drug plasma levels
Nov, 2034

(11 years from now)

US9474731 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9375429 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(11 years from now)

US9421176 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9408815 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9763932 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11311534 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9205083 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(11 years from now)

US9707191 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10898453 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11433067 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9700528 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9370513 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9457023 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9238032 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US11096937 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11298352 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10966941 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11298351 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11090300 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10894047 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10064857 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11291665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11291638 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10786469 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11253492 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10881657 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10874663 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10799497 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(11 years from now)

US11058648 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11273133 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10864209 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10806710 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10881624 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10786496 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11020389 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11185515 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10945973 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11285146 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11285118 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10596167 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US11439636 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9314462 AXSOME Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9198905 AXSOME Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11426401 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11426370 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11419867 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10772850 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11273134 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11253491 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11234946 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10548857 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11229640 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(11 years from now)

US10874665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10780066 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

Do you want to check out AUVELITY patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; Dextromethorphan and bupropion in combination to increase dextromethorphan plasma levels

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

AUVELITY family patents

198

United States

15

China

12

Australia

11

Korea, Republic of

10

Japan

9

Canada

9

European Union

8

Israel

8

New Zealand

8

Singapore

3

Ecuador

3

Peru

3

Costa Rica

3

Mexico

3

Brazil

2

Colombia

2

Malaysia

2

Chile

1

Croatia

1

Denmark

1

Spain

1

Nicaragua

1

Portugal

1

Poland

1

Morocco

1

Hong Kong

1

Slovenia

1

RS

1

Hungary

1

Lithuania

11. List of Ayvakit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(11 years from now)

Do you want to check out AYVAKIT patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 9, 2025
New Indication (I) Jun 16, 2024
Orphan Drug Exclusivity (ODE) Jan 9, 2027

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 2024-01-10

Market Authorisation Date: 09 January, 2020

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastoc...

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

9

United States

3

Hungary

2

Spain

2

Portugal

2

Poland

2

Japan

2

China

2

Lithuania

2

European Union

1

Australia

1

Israel

1

Croatia

1

Korea, Republic of

1

Canada

1

Netherlands

1

New Zealand

1

Denmark

1

Uruguay

1

Cyprus

1

Singapore

1

Philippines

1

Russia

1

Norway

1

Hong Kong

1

Slovenia

1

Mexico

1

Argentina

1

Brazil

1

RS

1

South Africa

1

Taiwan

12. List of Barhemsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9084765 ACACIA Use of amisulpride as an anti-emetic
Feb, 2034

(10 years from now)

Do you want to check out BARHEMSYS patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: 2024-02-27

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

BARHEMSYS family patents

10

United States

3

Croatia

3

Denmark

3

Spain

3

Cyprus

3

Portugal

3

Poland

3

Slovenia

3

Mexico

3

RS

3

European Union

2

Japan

2

United Kingdom

2

San Marino

1

Australia

EA

1

EA

1

Israel

1

Korea, Republic of

1

Canada

1

New Zealand

1

Norway

1

Hong Kong

1

Brazil

1

China

1

Hungary

1

Lithuania

13. List of Bosulif drug patents

BOSULIF's oppositions filed in EPO
BOSULIF Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103497 PF PRISM CV Treatment of imatinib resistant leukemia
Feb, 2034

(10 years from now)

Do you want to check out BOSULIF patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 19, 2024

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 04 September, 2012

Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject...

Dosage: TABLET;ORAL

How can I launch a generic of BOSULIF before it's patent expiration?
More Information on Dosage

BOSULIF family patents

4

European Union

3

Canada

3

Japan

3

United States

2

Denmark

2

Spain

2

Portugal

2

Poland

2

Slovenia

1

Panama

1

Australia

1

Korea, Republic of

1

Chile

1

Cyprus

1

Russia

1

Hong Kong

1

Mexico

1

Brazil

1

China

1

South Africa

1

Hungary

1

Taiwan

14. List of Brukinsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(10 years from now)

US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(10 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(10 years from now)

Do you want to check out BRUKINSA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Orphan Drug Exclusivity (ODE) Sep 14, 2028
New Indication (I) Sep 14, 2024

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: 2023-11-15

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; For the treatment of patients with waldenstrom's macroglobulinemia; Relapsed or refractory marginal ...

Dosage: CAPSULE;ORAL

More Information on Dosage

BRUKINSA family patents

5

United States

3

China

2

Hungary

2

Lithuania

1

Australia

EA

1

EA

1

Croatia

1

Korea, Republic of

1

Canada

1

Netherlands

1

New Zealand

1

Denmark

1

Spain

1

Cyprus

1

Singapore

1

Portugal

1

Poland

1

Japan

1

Hong Kong

1

Slovenia

1

Mexico

1

RS

1

Brazil

1

South Africa

1

European Union

15. List of Camzyos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

Do you want to check out CAMZYOS patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 28, 2029
New Chemical Entity Exclusivity (NCE) Apr 28, 2027

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: 2026-04-28

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage

CAMZYOS family patents

12

United States

4

Australia

3

Israel

3

Korea, Republic of

3

Japan

EA

2

EA

2

Singapore

2

China

2

European Union

1

Croatia

1

Dominican Republic

1

Canada

1

New Zealand

1

Denmark

1

Spain

1

Tunisia

1

Peru

1

Malaysia

1

Costa Rica

1

Chile

1

Portugal

1

Ukraine

1

Philippines

1

Poland

1

Morocco

1

Hong Kong

1

Slovenia

1

Guatemala

1

Mexico

1

Brazil

1

South Africa

1

RS

1

Hungary

1

Lithuania

16. List of Caplyta drug patents

CAPLYTA's oppositions filed in EPO
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026951 INTRA-CELLULAR Methods of treating bipolar disorder
Dec, 2034

(11 years from now)

US9956227 INTRA-CELLULAR Method for the treatment of residual symptoms of schizophrenia
Dec, 2034

(11 years from now)

US10960009 INTRA-CELLULAR Methods of treating schizophrenia and depression
Dec, 2034

(11 years from now)

Do you want to check out CAPLYTA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 2023-12-21

Market Authorisation Date: 20 December, 2019

Treatment: Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

12

United States

5

Korea, Republic of

4

Australia

3

Canada

3

Japan

2

China

2

Israel

2

European Union

1

Mexico

1

Denmark

1

Portugal

1

Hungary

1

Spain

1

Russia

1

Poland

17. List of Cibinqo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(10 years from now)

US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(10 years from now)

Do you want to check out CIBINQO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 14, 2027
New Patient Population (NPP) Feb 9, 2026

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: 2026-01-14

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage

CIBINQO family patents

4

United States

3

Hungary

3

Lithuania

2

Croatia

2

Denmark

2

Spain

2

ME

2

Cyprus

2

Portugal

2

Poland

2

Japan

2

Slovenia

2

RS

2

China

2

European Union

1

Australia

EA

1

EA

1

Israel

IB

1

IB

1

Dominican Republic

1

Korea, Republic of

1

Moldova, Republic of

1

Canada

1

Netherlands

1

New Zealand

1

Tunisia

1

Uruguay

1

Peru

1

Malaysia

1

Costa Rica

1

Chile

1

Singapore

1

Ukraine

1

Philippines

1

Morocco

1

Norway

1

Hong Kong

1

Mexico

1

Georgia

1

Argentina

1

South Africa

1

Cuba

1

Brazil

1

Turkey

1

Taiwan

18. List of Clenpiq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624879 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(11 years from now)

US11191753 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(11 years from now)

US9827231 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(11 years from now)

Do you want to check out CLENPIQ patents from before 2022?

Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy

Dosage: SOLUTION;ORAL

How can I launch a generic of CLENPIQ before it's patent expiration?
More Information on Dosage

CLENPIQ family patents

4

United States

2

Korea, Republic of

1

Canada

1

Mexico

1

China

1

Australia

1

Russia

1

Spain

1

Japan

1

European Union

19. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231964 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(11 years from now)

US10835527 NALPROPION Compositions and methods for reducing major adverse cardiovascular events
Jul, 2034

(11 years from now)

US10828294 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(11 years from now)

Do you want to check out CONTRAVE patents from before 2022?

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

CONTRAVE family patents

16

United States

2

Korea, Republic of

2

Japan

2

Argentina

2

China

2

European Union

1

Ecuador

1

Australia

EA

1

EA

1

Israel

1

Croatia

1

Canada

1

New Zealand

1

Denmark

1

Spain

1

Tunisia

1

Uruguay

1

Peru

1

Costa Rica

1

Chile

1

Singapore

1

Portugal

1

Russia

1

Poland

1

Morocco

1

Slovenia

1

Mexico

1

RS

1

Hungary

1

Taiwan

1

Lithuania

20. List of Cosela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10085992 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(10 years from now)

US10966984 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(10 years from now)

US11040042 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(10 years from now)

US9487530 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(10 years from now)

Do you want to check out COSELA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 2025-02-12

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell l...

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

COSELA family patents

26

United States

10

Japan

6

China

4

Canada

4

Hong Kong

4

European Union

1

Slovenia

1

Cyprus

1

RS

1

ME

1

Denmark

1

Hungary

1

Portugal

1

Spain

1

Poland

1

Croatia

1

Lithuania

21. List of Cotellic drug patents

COTELLIC's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11087354 GENENTECH INC Combination therapies
Jun, 2034

(11 years from now)

US11087354

(Pediatric)

GENENTECH INC Combination therapies
Dec, 2034

(11 years from now)

Do you want to check out COTELLIC patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Oct 28, 2025
M (M) Jul 28, 2025
Orphan Drug Exclusivity (ODE) Oct 28, 2029
Pediatric Exclusivity (PED) Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage

COTELLIC family patents

7

United States

5

Korea, Republic of

3

New Zealand

3

Singapore

2

Canada

2

Japan

2

China

2

European Union

1

Colombia

1

Australia

EA

1

EA

1

Israel

1

Croatia

1

Denmark

1

Spain

1

Peru

1

Malaysia

1

Costa Rica

1

Chile

1

Portugal

1

Ukraine

1

Philippines

1

Poland

1

Morocco

1

Hong Kong

1

Slovenia

1

Mexico

1

Brazil

1

South Africa

1

RS

1

Hungary

1

Lithuania

22. List of Dexycu Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159683 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(10 years from now)

US10028965 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(10 years from now)

US10022502 EYEPOINT PHARMS Dose guides for injection syringe
Jun, 2034

(11 years from now)

Do you want to check out DEXYCU KIT patents from before 2022?

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: Treatment of postoperative inflammation

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

DEXYCU KIT family patents

13

United States

3

Korea, Republic of

3

China

3

European Union

2

Australia

2

Canada

2

Spain

2

Japan

1

Croatia

1

New Zealand

1

Denmark

1

Portugal

1

Poland

1

Slovenia

1

Mexico

1

Brazil

1

RS

1

Hungary

1

Lithuania

23. List of Dificid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds
May, 2034

(10 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds
Nov, 2034

(11 years from now)

Do you want to check out DIFICID patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Jan 24, 2023
Orphan Drug Exclusivity (ODE) Jan 24, 2027
Pediatric Exclusivity (PED) Jul 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 24 January, 2020

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of DIFICID before it's patent expiration?
More Information on Dosage

DIFICID family patents

3

European Union

1

Australia

EA

1

EA

1

Croatia

1

Korea, Republic of

1

Moldova, Republic of

1

Canada

1

New Zealand

1

Denmark

1

Spain

1

Cyprus

1

Jordan

1

Portugal

1

Ukraine

1

Poland

1

Japan

1

Slovenia

1

Georgia

1

Argentina

1

RS

1

China

1

South Africa

1

Hungary

1

United States

1

Taiwan

1

Lithuania

24. List of Dilaudid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(10 years from now)

Do you want to check out DILAUDID patents from before 2022?

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 January, 1984

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID before it's patent expiration?
More Information on Dosage

DILAUDID family patents

6

United States

3

European Union

2

China

2

Australia

1

Canada

1

Brazil

1

Denmark

1

Portugal

1

Spain

1

Japan

1

Hong Kong

25. List of Doryx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511031 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(11 years from now)

US9295652 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(11 years from now)

US9446057 MAYNE PHARMA Controlled release doxycycline
Dec, 2034

(11 years from now)

Do you want to check out DORYX patents from before 2022?

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 06 May, 2005

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of DORYX before it's patent expiration?
More Information on Dosage

DORYX family patents

7

United States

26. List of Durysta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(11 years from now)

US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(11 years from now)

Do you want to check out DURYSTA patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

7

United States

4

European Union

3

Australia

2

Israel

2

Denmark

2

Spain

2

Singapore

2

Portugal

2

Poland

2

Japan

2

Slovenia

2

Mexico

2

China

2

Hungary

1

Korea, Republic of

1

Canada

1

New Zealand

1

Saudi Arabia

1

Chile

1

Cyprus

1

Ukraine

1

Philippines

1

Russia

1

Norway

1

Hong Kong

1

South Africa

1

Turkey

27. List of Epclusa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086011 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US9757406 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

US9757406

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US10086011

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Do you want to check out EPCLUSA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
New Strength (NS) Mar 19, 2023
M (M) Apr 27, 2025
New Patient Population (NPP) Mar 19, 2023
Pediatric Exclusivity (PED) May 15, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 28 June, 2016

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

EPCLUSA family patents

11

United States

3

Australia

3

European Union

2

Spain

2

Portugal

2

Poland

2

Japan

2

Hong Kong

2

Slovenia

EA

1

EA

1

Korea, Republic of

1

Canada

1

New Zealand

1

Uruguay

1

Singapore

1

Mexico

1

Argentina

1

China

1

Taiwan

28. List of Epinephrine drug patents

EPINEPHRINE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039728 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(11 years from now)

US10004700 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(11 years from now)

US9283197 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(11 years from now)

Do you want to check out EPINEPHRINE patents from before 2022?

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 29 July, 2014

Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating...

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

How can I launch a generic of EPINEPHRINE before it's patent expiration?
More Information on Dosage

29. List of Evomela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10040872 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same
Jan, 2034

(10 years from now)

Do you want to check out EVOMELA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's patent expiration?
More Information on Dosage

EVOMELA family patents

6

United States

EA

2

EA

2

Chile

2

Japan

2

Hong Kong

2

South Africa

1

Australia

1

Israel

1

Korea, Republic of

1

Canada

1

New Zealand

1

Malaysia

1

Singapore

1

Ukraine

1

Philippines

1

Mexico

1

Brazil

1

China

1

European Union

30. List of Evzio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Jul, 2034

(11 years from now)

Do you want to check out EVZIO patents from before 2022?

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

2

United States

31. List of Evzio (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Jul, 2034

(11 years from now)

Do you want to check out EVZIO (AUTOINJECTOR) patents from before 2022?

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

2

United States

32. List of Exondys 51 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9506058 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(10 years from now)

US10364431 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(10 years from now)

US10337003 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(10 years from now)

Do you want to check out EXONDYS 51 patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

Market Authorisation Date: 19 September, 2016

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in ...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

EXONDYS 51 family patents

11

United States

3

Australia

3

Israel

2

Mexico

2

China

2

New Zealand

2

Japan

2

Korea, Republic of

2

European Union

1

Canada

1

Brazil

EA

1

EA

1

Hong Kong

33. List of Firdapse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10793893 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
May, 2034

(10 years from now)

Do you want to check out FIRDAPSE patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 28, 2023
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Patient Population (NPP) Sep 29, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: 2022-11-28

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

More Information on Dosage

FIRDAPSE family patents

13

United States

1

Canada

34. List of Fulvestrant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188663 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(10 years from now)

US9833459 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(10 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations
May, 2034

(10 years from now)

Do you want to check out FULVESTRANT patents from before 2022?

Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

FULVESTRANT family patents

5

United States

35. List of Furoscix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11433044 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(10 years from now)

US9884039 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(10 years from now)

US10272064 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(10 years from now)

Do you want to check out FUROSCIX patents from before 2022?

Drugs and Companies using FUROSEMIDE ingredient

Market Authorisation Date: 07 October, 2022

Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

FUROSCIX family patents

6

United States

2

Singapore

2

Japan

2

Korea, Republic of

2

European Union

1

Canada

1

Mexico

1

Brazil

1

China

1

Australia

1

Denmark

1

Israel

1

Portugal

1

Spain

1

Hong Kong

36. List of Ganzyk-rtu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486530 EXELA PHARMA Ganciclovir compositions and related methods
Sep, 2034

(11 years from now)

Do you want to check out GANZYK-RTU patents from before 2022?

Drugs and Companies using GANCICLOVIR ingredient

Market Authorisation Date: 17 February, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

37. List of Giapreza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559559 LA JOLLA PHARMA NA
Dec, 2034

(11 years from now)

US9220745 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10028995 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10493124 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US11096983 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

Do you want to check out GIAPREZA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: 2021-12-21

Market Authorisation Date: 21 December, 2017

Treatment: Increasing blood pressure in a patient having distributive shock; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and re...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's patent expiration?
More Information on Dosage

GIAPREZA family patents

9

United States

3

Japan

3

China

2

Australia

EA

2

EA

2

Korea, Republic of

2

European Union

1

Israel

1

Croatia

1

Canada

1

New Zealand

1

Denmark

1

Spain

1

Cyprus

1

Portugal

1

Poland

1

Slovenia

1

Mexico

1

Brazil

1

RS

1

Hungary

1

Lithuania

38. List of Givlaari drug patents

Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

Do you want to check out GIVLAARI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 2023-11-21

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents